For many patients treated for thyroid cancer, the hope after surgery and therapy is simple: “never again.” 

While the prognosis for thyroid cancer (especially well-differentiated thyroid cancers like papillary and follicular types) is generally excellent, recurrence does occur. The key to good outcomes lies not in avoiding follow-up, but in understanding and managing the risk of recurrence wisely.

How often does thyroid cancer recur?

Globally, the recurrence for well-differentiated thyroid cancer has been reported in roughly 7 to 14 percent of patients after initial treatment. Most recurrences are detected within the first 10 years of follow-up.

In Filipino patients, emerging literature suggests that recurrence may be higher than commonly seen in other populations. Some studies indicate that Filipinos, both in the Philippines and abroad, have a trend toward increased incidence and recurrence compared with non-Filipino groups.

For example, in a long-term US cohort, Filipino patients with thyroid cancer experienced a recurrence rate of 25 percent, compared with about 9.5 percent in non-Filipino patients, even when other clinical factors were similar.

While national registry data in the Philippines is still limited, this higher recurrence trend reinforces why local and international guidelines emphasize careful long-term surveillance for all thyroid cancer survivors.

What about thyroid cancer in the Philippines?

Thyroid cancer is among the more common cancers in the Philippines. It is the seventh most common cancer overall in the country. In 2020, there were an estimated 6,345 new thyroid cancer cases in the Philippines, accounting for roughly 4.1 percent of all new cancers recorded that year. The disease affects women significantly more than men.

These trends underscore why awareness and follow-up are public health priorities.

Why do recurrences happen?

Recurrence usually does not mean the initial treatment was inadequate. Most recurrences reflect microscopic disease that was below detection at the time of surgery or therapy. Key factors that may increase recurrence risk include:

•Lymph node involvement at diagnosis

•Large initial tumor size

•More aggressive histologic subtypes

•Complete removal of thyroid tissue was not possible

Higher initial risk category

Genetic and environmental factors may also play a role, and ongoing research continues to deepen our understanding.

How can recurrence be prevented?

There’s no foolproof way to prevent recurrence, but proactive care can lower risk and improve early detection.

Risk-adapted initial treatment: Choosing the right extent of surgery and use of radioactive iodine (RAI) when indicated. If thyroid cancer is suspected, majority of patients have a complete removal of the thyroid gland (total thyroidectomy), followed by RAI.

Thyroid hormone suppression therapy: Taking thyroid hormone (levothyroxine) not only replaces what is missing after the thyroid is removed. The dose prescribed is adjusted to keep thyroid-stimulating hormone (TSH) at a low level to help reduce stimulation of residual cancer cells.

Structured follow-up: Regular follow-up with blood tests (including thyroglobulin levels) and neck ultrasound can help detect recurrence early before symptoms develop.  

Patient compliance: Consistent and proper medication use, and attendance at follow-up appointments matter (usually every three months).  Levothyroxine should be taken at the dose prescribed in the morning, on an empty stomach, with only water.  Wait at least 30 minutes after taking levothyroxine before taking any other food, drink or medication. Even if you do not have breakfast, you can and should take your levothyroxine. 

How is recurrence managed?

If recurrence is detected:

• Surgery is often the first option for recurrence in the area of the thyroid or with suspicious lymph nodes 

•Radioactive iodine (RAI) therapy may be used again if the recurrent disease is small and appears responsive to RAI

•Close monitoring is sometimes appropriate for very small recurrences that do not markedly increase in size over time

•Advanced or metastatic recurrence may require targeted therapy or multidisciplinary care, involving other physicians such as oncologists and radiologists.

The good news is that even when thyroid cancer returns, most patients continue to do well with proper management.

Living beyond recurrence risk

Being a thyroid cancer survivor means an ongoing partnership with your healthcare team to prevent and detect recurrence. Recurrence isn’t a sign of failure — it’s part of the natural history of the disease for some patients. Early detection and timely intervention remain the most powerful tools we have.

With consistent follow-up, informed care and a trusted medical partnership, survivors can live fully — not in the shadow of disease, but in the confidence that recurrence, if it happens, can be managed. The goal is not just survival, but a life well lived beyond cancer.

Last week was Goiter Awareness Week, observed annually during the fourth week of January in the Philippines. This observance was established by Presidential Proclamation No. 1188, signed on 11 December 2006, to raise public awareness.  

The Department of Health leads the observance, coordinating with organizations such as the Philippine College of Endocrinology, Diabetes and Metabolism and the Philippine Thyroid Association to promote education and preventive measures related to thyroid health.